Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 308 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is B  [Clear All Filters]
2020
Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, Gilmore SP, Spasojevic I, Corcoran DL, Young CC et al..  2020.  Efficacy of osimertinib against EGFRvIII+ glioblastoma.. Oncotarget. 11(22):2074-2082.
Nosyk B, Zang X, Krebs E, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Golden M et al..  2020.  Ending the HIV epidemic in the USA: an economic modelling study in six cities.. Lancet HIV.
Ghomrawi HMK, Mushlin AI, Kang R, Banerjee S, Singh JA, Sharma L, Flink C, Nevitt M, Neogi T, Riddle DL.  2020.  Examining Timeliness of Total Knee Replacement Among Patients with Knee Osteoarthritis in the U.S.: Results from the OAI and MOST Longitudinal Cohorts.. J Bone Joint Surg Am. 102(6):468-476.
Ezeomah C, Cunningham KA, Stutz SJ, Fox RG, Bukreyeva N, Dineley KT, Paessler S, Cisneros IE.  2020.  Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats.. Brain Behav Immun.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Behrends CN, Gutkind S, Deming R, Fluegge KR, Bresnahan MP, Schackman BR.  2020.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.. J Urban Health.
Behrends CN, Gutkind S, Deming R, Fluegge KR, Bresnahan MP, Schackman BR.  2020.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.. J Urban Health.